IQVIA CORE OBESITY AND DIABETES MODEL (CODM)

Modeling the impact of cardiometabolic disease interventions

Use the Core Obesity and Diabetes Model to simulate long‑term progression and impact of interdependent cardiometabolic diseases within a population. Apply these insights to help support HTA submissions, value assessments and policy decision‑making
CONTACT US
Solutions Real World Evidence Health Economics and Value Core Obesity and Diabetes Model (CODM)

The Core Obesity & Diabetes Model (CODM)

Designed for broad relevance, the model resonates across the healthcare ecosystem from pharma, medtech, and emerging biopharma players to public institutions like the NHS, HTA bodies, NGOs, and private insurers. CODM is underpinned by our widely accepted legacy tool, the Core Diabetes Model (CDM), recognized across stakeholders including all major HTA bodies.

All-in-one

Integrated modelling of cardiometabolic diseases within a single framework

Long-Term Value

Translates short-term health outcomes into long-term projections and supports a wide range of applications, including HTA submissions, public health policy assessments, and awareness studies

Multistate Modelling

Designed to assess health and economic outcomes in patients across all combinations of obesity, prediabetes, or Type 2 Diabetes status for drugs, medical devices, healthcare interventions and policy programs

Comprehensive Cardiometabolic Modelling Framework

10+

cardiometabolic conditions modelled​​

150+

clinical endpoints measured​

20+

clinical risk factors dynamically evolving over time ​

60+

cost outcomes calculated​

Up to 100

years time horizon​

20+

lines of treatment supported​

Delivering meaningful solutions

Assessing Value for Money

Highlights the key value drivers of new health technologies, revealing their cost‑effectiveness, financial impact, long‑term outcomes, and the real benefits they deliver to patients

  • Is drug X more cost-effective than drug Y?
  • Is the medical device more cost-effective than W?
  • Which is the Budget Impact associated to the introduction of X ?
  • Which are the long-term health impacts of introducing a new technology in the population?
  • How does a drug impact QoL of patients?

Informing Population Health Planning

Helps estimate future event rates in the population and quantify the potential savings and health benefits of improving treatment adherence

  • How many events should we expect in the population in the next years if no changes occurs?
  • Which saving or health impacts may be associated to higher therapeutic adherence?

Measuring the Impact of Policy Decisions

Understands the savings and health benefits of early diagnosis or educational programs, and comparing the cost‑effectiveness of different policy options

  • Which saving or health impacts would be associated to increasing early diagnosis or educational programs?
  • Is policy A more cost-effective than policy B?

Shaping the Future of Cardiometabolic Diseases

Offers forward‑looking insights into how cardiometabolic diseases will evolve over time and how demographic and socioeconomic trends will drive future health and cost pressures

  • What is the long-term burden of cardiometabolic diseases in a given country?
  • How demographic changes will impact the future burden of cardiometabolic diseases ?
  • How do socioeconomic factors influence the future burden of cardiometabolic diseases?
Key Benefits

Practical interface – Fast, Scalable, Secure

Technical features

Scientifically Rigorous Simulations Proven to Deliver

Stochastic Patient‑Level Markov Modelling

Patient‑level modelling approach incorporating first‑order stochastic uncertainty, combined with a network of interdependent Markov state sub‑models

NICE‑Aligned Monte Carlo simulation

Implements a two‑level Monte Carlo simulation framework, consistent with NICE Decision Support Unit guidance on probabilistic analysis and bootstrapping

Granular Insights Across the Full Disease Continuum

Coverage across the full disease continuum, including individuals without morbidity​ with granular analysis of distinct patient sub‑populations​

Modelling of Real‑World Treatment Pathways

Explicit modelling of real‑world treatment behavior, including non‑adherence, switching and discontinuation​

Learn more

Thought Leadership

Scientific Poster
Internal Validation of Type 2 Diabetes and Cardiovascular Events Incidence in the Core Obesity and Diabetes Model

ISPOR Europe 2025 Poster
Institute Report
Rethinking Obesity

Impact on Healthcare Economics and Clinical Practice

Explore More

Market Access Insights

Market Access Insights provides access to HTA, reimbursement, regulatory, clinical trial, and pricing information so that you can make more informed market access decisions.

Tackling Obesity

Obesity, a pervasive global health challenge, transcends borders, impacting millions with profound consequences to their well-being and quality of life.

Contact Us